SpringerLink
Log in

The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Although the survival rate of diffuse large B cell lymphoma (DLBCL) has increased with years, there are still patients who do not achieve complete remission or who relapse, especially patients with activated B cell-like (ABC) DLBCL. Bortezomib, a proteasome inhibitor, has shown activity in diffuse large B cell lymphoma, especially in the subtype of ABC DLBCL. We conducted a meta-analysis to compare the efficacy and adverse events in bortezomib-containing regimens with standard R-CHOP regimen in treating DLBCL. Our results show that comparing to standard R-CHOP regimen, bortezomib-containing regimen could not prolong the survival in patients with ABC DLBCL. And patients who received bortezomib had a trend of higher risk with peripheral neuropathy, although there is no significant statistical difference.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC et al (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8(1):68–74

    Article  CAS  Google Scholar 

  2. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937–1947

    Article  Google Scholar 

  3. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin

  4. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, Mate JL, Sancho JM, Arenillas L, Serrano S, Escoda L, Martinez S, Valera A, Martinez A, Jares P, Pinyol M, Garcia-Herrera A, Martinez-Trillos A, Gine E, Villamor N, Campo E, Colomo L, Lopez-Guillermo A, for the Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) (2011) Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 117(18):4836–4843

    Article  CAS  Google Scholar 

  5. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861–1874

    Article  CAS  Google Scholar 

  6. Odqvist L, Montes-Moreno S, Sanchez-Pacheco RE, Young KH, Martin-Sanchez E, Cereceda L et al (2014) NFkappaB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Mod Pathol 27(10):1331–1337

    Article  CAS  Google Scholar 

  7. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61(9):3535–3540

    CAS  PubMed  Google Scholar 

  8. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C (2008) Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res 14(13):4175–4185

    Article  CAS  Google Scholar 

  9. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609–2617

    Article  CAS  Google Scholar 

  10. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol Off J Am Soc Clin Oncol 30(24):2946–2955

    Article  CAS  Google Scholar 

  11. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 24(30):4867–4874

    Article  Google Scholar 

  12. Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N (2009) Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 115(19):4540]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/886/CN-00728886/frame.html–4546

    Article  CAS  Google Scholar 

  13. Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, Ferhanoglu B (2015) Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 126(16):1893–1901

    Article  CAS  Google Scholar 

  14. Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S (2017) Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 35(31):3538–3546

    Article  Google Scholar 

  15. Gonzalez-Barca E, Carrillo E, Grande C, Martín A, Montes-Moreno S, Coronado M, Mercadal S, Roncero JM, Perez de Oteyza J, Nicolas C, Rodriguez-Salazar MJ, Sancho JM, Palomera L, Lopez J, Albo C, Peñalver FJ, Hernandez JA, Lopez-Guillermo A, Ramirez MJ, Jarque I, Bargay J, Canales M, Conde E, Caballero D (2017) Phase 2 randomized trial comparing standard RCHOP versus BRCAP as first line treatment in young patients with high-risk DLBCL. A study from Spanish group geltamo. Hematol Oncol 35((Gonzalez-Barca E.; Mercadal S.) Hematology, Instituto Catalan de Oncologia-l'Hospitalet, Barcelona, Spain):188–189

    Article  Google Scholar 

  16. Davies AJ, Barrans S, Maishman T, Cummin TE, Bentley M, Mamot C, Novak U, Caddy J, Hamid D, Kazmi-Stokes SH, Mcmillan A, Fields PA, Pocock C, Kruger A, Collins G, Sha C, Clipson A, Wang M, Tooze RM, Care MA, Griffiths GO, du M, Westhead DR, Burton C, Jack A, Johnson PW (2017) Differential efficacy of bortezomib in subtypes of diffuse large B-cell lymphoma (DLBL): a prospective randomised study stratified by transcriptome profiling: REMoDL-B. Hematol Oncol 35(Davies A.J.; Cummin T.E.; Caddy J.; Kazmi-Stokes S.H.; Johnson P.W.) Cancer Research UK Centre, University of Southampton (PMAL Consortium), Southampton, United Kingdom):130–131

    Article  Google Scholar 

  17. Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D et al (2010) Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 115(3):475–480

    Article  Google Scholar 

  18. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR (2014) Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk 14(6):460–7 e2

    Article  Google Scholar 

  19. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 33(3):251–257

    Article  CAS  Google Scholar 

  20. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y (2014) Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 15(9):1019–1026

    Article  CAS  Google Scholar 

  21. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank all of our colleagues who contributed to this systematic review and meta-analysis.

Author information

Author notes

  1. Zhijuan Lin, **ng Chen and Zhifeng Li contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, The First Affiliated Hospital of **amen University, 55 Zhenhai Road, **amen, 361003, Fujian, People’s Republic of China

    Zhijuan Lin, Zhifeng Li, Yong Zhou, Zhihong Fang, Yiming Luo, **tao Zhao & Bing Xu

  2. Department of Nephrology, The First Affiliated Hospital of **amen University, 55 Zhenhai Road, **amen, 361003, Fujian, People’s Republic of China

    **ng Chen

Authors
  1. Zhijuan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. **ng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhifeng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhihong Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yiming Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. **tao Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yiming Luo, **tao Zhao or Bing Xu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, Z., Chen, X., Li, Z. et al. The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis. Ann Hematol 97, 2137–2144 (2018). https://doi.org/10.1007/s00277-018-3435-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3435-1

Keywords

Search

Navigation